Immunome, Inc. (IMNM)
Nasdaq · Healthcare · Biotechnology
$21.17+1.29%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.4B
- 52-week range
- $13.41 – $30.06
- 52-week change
- +51.23%
- EPS (trailing)
- −$2.52
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $6.9M (−23.23%)
- Net income
- −$212M
- Operating margin
- −3228.8%
- Diluted EPS
- −$2.43
- Free cash flow
- −$201M
From the company’s annual report on SEC EDGAR.
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Headquarters: Bothell, United States · 247 employees · immunome.com